Investigating the role of Levosimendan (a drug which improves the performance of the heart) on patients with heart disease

Evaluation of Levosimendan in patients with coronary artery disease with diastolic dysfunction

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/10/005149

Enrollment

Registered

2014-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Coronary artery disease

Interventions

Intervention1: Levosimendan: An inotrope with coronary dilator. It will be started intravenously after sternotomy at a loading dose of 10mic/kg/min for 10 minutes followed by an infusion at 0.1mic/kg/

Eligibility

Inclusion criteria

Inclusion criteria: Coronary artery disease with diastolic dysfunction undregoing coronary artery bypass grafting

Exclusion criteria

Exclusion criteria: Patients in cardiogenic shock, in sepsis, in renal/hepatic/respiratory failure, not willing to be part of the study

Design outcomes

Primary

Measure	Time frame
ICU stayTimepoint: Once the patient is shifted to the ICU, the duration of ICU stay, mechanical ventialtion and secondary complications will be noted	—

Secondary

Measure	Time frame
Duration of mechanical ventilation and improvement in diastolic functionTimepoint: hours	—

Countries

India

Contacts

Public ContactDr Vishwas Malik

All India Institute of Medical Sciences

aruncardiac@live.com09968721687

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026